Search Results - "Christiaans, M. H. L."

Preservation of kidneys from controlled donors after cardiac death by Wind, J., Snoeijs, M. G. J., van der Vliet, J. A., Winkens, B., Christiaans, M. H. L., Hoitsma, A. J., van Heurn, L. W. E.

“…Background: Donation after cardiac death (DCD) expands the pool of donor kidneys, but is associated with warm ischaemic injury. Two methods are used to…”
Get full text

Histological Assessment of Preimplantation Biopsies May Improve Selection of Kidneys from Old Donors After Cardiac Death by Snoeijs, M. G. J., Buurman, W. A., Christiaans, M. H. L., Van Hooff, J. P., Goldschmeding, R., Van Suylen, R. J., Peutz‐Kootstra, C. J., Van Heurn, L. W. E.

“…Kidneys from old donors after cardiac death (DCD) may increase the donor pool but the prognosis of these kidneys is unsatisfactory. To improve these results,…”
Get full text

External validation of a model to predict risk of keratinocyte skin cancer after renal transplantation in a Western European cohort by Verhage, E.J., Nelemans, P.J., Kuijk, S.M.J., Christiaans, M.H.L., Kelleners‐Smeets, N.W.J.

Get full text

Cervicovaginal HPV Infection in Female Renal Transplant Recipients: An Observational, Self‐Sampling Based, Cohort Study by Meeuwis, K. A. P., Hilbrands, L. B., IntHout, J., Slangen, B. F. M., Hendriks, I. M. P., Hinten, F., Christiaans, M. H. L., Quint, W. G. V., van de Kerkhof, P. C. M., Massuger, L. F. A. G., Hoitsma, A. J., van Rossum, M. M., Melchers, W. J. G., de Hullu, J. A.

“…Immunosuppressive treatment of organ transplant recipients is associated with an increase in the occurrence of human papillomavirus (HPV) related anogenital…”
Get full text

How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies? by Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M., Bots, M. L., Drop, A. C. A. D., Plaisier, L., Seelen, M. A. J., Sanders, J. S. F., Hepkema, B. G., Lambeck, A. J., Bungener, L. B., Roozendaal, C., Tilanus, M. G. J., Vanderlocht, J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H. L., van Ittersum, F. J., Nurmohamed, A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J. M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J. M., de Fijter, J. W., Betjes, M. G. H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G.

“…Solid‐phase multiplex‐bead assays are widely used in transplantation to detect anti‐human leukocyte antigen (HLA) antibodies. These assays enable high…”
Get full text

The Maastricht Transplant Center: Clinical setting and epitope searches in HLA class II molecules: Does the structural localization of a polymorphic site contribute to its immunogenicity? by Schellekens, J, Vanderlocht, J, Groeneweg, M, Voorter, C.E, Wieten, L, Gelens, M.A, van Duijnhoven, E.M, van Heurn, L.W.E, Christiaans, M.H.L, Tilanus, M.G.J

“…Abstract Our understanding of the immunological processes influencing the clinical outcome after kidney transplantation has advanced majorly over the last few…”
Get full text

Glucose Metabolic Disorder After Transplantation by Van Hooff, J. P., Christiaans, M. H. L., Van Duijnhoven, E. M.

“…Better evidence on the relative merits of various immunosuppressive regimens for reducing diabetes while preserving overall outcomes is needed. See also…”
Get full text

Luminex donor-specific crossmatches by Billen, E. V. A., Voorter, C. E. M., Christiaans, M. H. L., Van Den Berg-Loonen, E. M.

“…In Luminex bead‐based screening assays, color‐coded microspheres coated with human leukocyte antigens (HLA) are used to identify both complement‐binding and…”
Get full text

Do Blood Pressure and Arterial Wall Properties Change After Conversion From Cyclosporine to Tacrolimus? by Gelens, M.A.C.J., Christiaans, M.H.L., Hooff, J.P.v.

“…Cardiovascular disease is the leading cause of death in renal transplant recipients. Arterial wall properties are surrogate markers for arteriosclerosis…”
Get full text

Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study by Tedesco-Silva, Helio, Pascual, Julio, Viklicky, Ondrej, Basic-Jukic, Nikolina, Cassuto, Elisabeth, Kim, Dean Y, Cruzado, Josep M, Sommerer, Claudia, Adel Bakr, Mohamed, Garcia, Valter D, Uyen, Huynh-Do, Russ, Graeme, Soo Kim, Myoung, Kuypers, Dirk, Buchler, Matthias, Citterio, Franco, Hernandez Gutierrez, Maria Pilar, Bernhardt, Peter, Chadban, Steve

“…BACKGROUND.The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in…”
Get full text

Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation by Boots, J.M.M, van den Ham, E.C.H, Christiaans, M.H.L, van Hooff, J.P

Get full text

Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant by Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., Reekum, F. E., Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C. A. D., Plaisier, L., Seelen, M. A. J., Sanders, J. S .F., Hepkema, B. G., Lambeck, A. J. A., Bungener, L. B., Roozendaal, C., Tilanus, M. G. J., Voorter, C. E., Wieten, L., Duijnhoven, E. M., Gelens, M., Christiaans, M. H. L., Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., Pant, K. A., Weerd, N. C., Berge, I. J. M., Bemelman, F. J., Hoitsma, A., Boog, P. J. M., Fijter, J. W., Betjes, M. G. H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G.

“…The presence of donor‐specific anti‐HLA antibodies (DSAs) is associated with increased risk of graft failure after kidney transplant. We hypothesized that DSAs…”
Get full text

Evaluation of prediction of tacrolimus area under the curve by trough concentrations by Stolk, L. M. L., Van Duijnhoven, E. M., Christiaans, M. H. L., Van Hooff, J. P.

Get full text

Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels by Artz, M.A, Boots, J.M.M, Ligtenberg, G, Roodnat, J.I, Christiaans, M.H.L, Hené, R.J, Blom, H.J, Demacker, P.N.M, Hilbrands, L.B

Get full text

Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after renal transplantation? by Boots, J.M.M, Christiaans, M.H.L, Undre, N.A, van Hooff, J.P

Get full text

Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients by van Duijnhoven, E.M, Christiaans, M.H.L, Boots, J.M.M, van Hooff, J.P

Get full text

HLA-DP antibodies before and after renal transplantation by Billen, E. V. A., Christiaans, M. H. L., Doxiadis, I. I. N., Voorter, C. E. M., Van Den Berg-Loonen, E. M.

“…Human leukocyte antigen (HLA)‐DP is considered a target for humoral immune response in clinical transplantation. This study analyses the incidence of HLA‐DP…”
Get full text

Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants by Billen, E. V. A., Christiaans, M. H. L., Van Den Berg-Loonen, E. M.

“…The clinical significance of the presence of donor‐specific anti‐human leucocyte antigen (HLA) antibodies (DSA) prior to renal transplantation detected solely…”
Get full text

Risk factors for cytomegalovirus infection and disease in renal transplant recipients: HLA-DR7 and triple therapy by Kraat, Y J, Christiaans, M H, Nieman, F H, van den Berg-Loonen, P M, van Hooff, J P, Bruggeman, C A

“…In a prospective study, an analysis of risk factors for the development of cytomegalovirus (CMV) infection and disease was performed on 77 renal allograft…”
Get more information

Letter to the Editor in Response to: Uncontrolled Donation After Cardiac Death: Potential for Future by Sharma et al by Hoogland, E. R. P., Christiaans, M. H. L., van Heurn, L. W. E.

Get full text